MedTrace Logo

This is a Study to Determine the Antidepressant Effects of AZD6765

NCT00986479 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2014-10-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.

Conditions

  • Treatment Resistant Major Depressive Disorder

Interventions

DRUG

AZD6765

Single IV infusion of 150 mg AZD6765.

DRUG

Placebo to AZD6765

Single IV infusion of Placebo to AZD6765

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Carlos A Zarate, MD · National Institute of Mental Health (NIMH)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00986479 on ClinicalTrials.gov